Fredun Pharmaceuticals (539730) Q4 07/08 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 07/08 earnings summary
30 Oct, 2026Executive summary
FY08 sales turnover reached Rs 467.66 lakh vs Rs 444.54 lakh; profit after tax rose to Rs 8.53 lakh from Rs 6.12 lakh.
Profit before interest and depreciation was Rs 54.62 lakh vs Rs 55.65 lakh; outlook was considered better on export orders in hand.
Financial highlights
Total income, including other income, was Rs 481.26 lakh vs Rs 453.39 lakh; expenditure was Rs 426.64 lakh vs Rs 397.73 lakh.
Profit before tax was Rs 7.08 lakh vs Rs 8.36 lakh, including Rs 2.87 lakh in prior-period/exceptional charges; reported PAT was Rs 8.53 lakh vs Rs 6.12 lakh.
Interest expense was Rs 24.49 lakh vs Rs 26.14 lakh; depreciation was Rs 20.18 lakh vs Rs 21.15 lakh.
Outlook and guidance
Sales turnover was slightly higher than the prior year; export orders on hand supported expectations for a better year ahead.
Latest events from Fredun Pharmaceuticals
- FY00 losses persisted as export disruption prompted a shift to direct markets and new products.539730
Q4 99/00 - Profit returned, but Rs 28.48 lakh of audit adjustments and debt risks clouded the outlook.539730Q4 00/01
- Turnover surged, but a deferred-tax charge and disputed excise refund clouded earnings.539730Q4 01/02
- Exports expanded as FY net profit reached ₹2.72 lakh despite accumulated losses.539730Q4 02/03
- Turnover grew 32% and the year returned to profit, despite significant audit qualifications.539730Q4 04/05
- Higher FY04 sales could not offset liquidity pressure and a Rs 14.11 lakh net loss.539730Q4 03/04
- Turnover plunged as beta-lactam production stopped and SEZ competition intensified.539730Q4 05/06
- Higher sales and profit, backed by export orders, alongside an AS 28 audit issue.539730Q4 06/07
- Lower revenue, weaker net profit, and export orders underpin a cautiously promising outlook.539730Q4 08/09